BioXcel Therapeutics Analyst Ratings
BioXcel Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | -16.48% | Goldman Sachs | $16 → $26 | Maintains | Neutral |
| 01/03/2023 | 134.5% | HC Wainwright & Co. | $85 → $73 | Maintains | Buy |
| 12/01/2022 | -48.6% | Goldman Sachs | → $16 | Upgrades | Sell → Neutral |
| 11/16/2022 | -42.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 11/11/2022 | -19.69% | Guggenheim | $28 → $25 | Maintains | Buy |
| 11/11/2022 | 144.14% | Canaccord Genuity | $75 → $76 | Maintains | Buy |
| 11/11/2022 | -42.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 08/24/2022 | 173.05% | HC Wainwright & Co. | $110 → $85 | Maintains | Buy |
| 07/07/2022 | -38.97% | Mizuho | → $19 | Initiates Coverage On | → Buy |
| 05/23/2022 | 253.36% | HC Wainwright & Co. | $134 → $110 | Maintains | Buy |
| 04/14/2022 | 330.45% | HC Wainwright & Co. | $130 → $134 | Maintains | Buy |
| 03/14/2022 | 317.6% | HC Wainwright & Co. | $140 → $130 | Maintains | Buy |
| 02/16/2022 | -19.69% | UBS | $88 → $25 | Maintains | Buy |
| 11/15/2021 | -22.9% | Goldman Sachs | $55 → $24 | Downgrades | Buy → Sell |
| 06/28/2021 | 349.73% | HC Wainwright & Co. | $176 → $140 | Maintains | Buy |
| 06/23/2021 | 301.54% | Truist Securities | $128 → $125 | Maintains | Buy |
| 06/01/2021 | 465.37% | HC Wainwright & Co. | $170 → $176 | Maintains | Buy |
| 05/11/2021 | 446.1% | HC Wainwright & Co. | $175 → $170 | Maintains | Buy |
| 04/09/2021 | 140.93% | Berenberg | → $75 | Initiates Coverage On | → Buy |
| 04/01/2021 | 205.17% | Canaccord Genuity | $110 → $95 | Maintains | Buy |
| 04/01/2021 | 307.97% | Truist Securities | $150 → $127 | Maintains | Buy |
| 04/01/2021 | 462.16% | HC Wainwright & Co. | $185 → $175 | Maintains | Buy |
| 02/01/2021 | 218.02% | UBS | → $99 | Initiates Coverage On | → Buy |
| 01/06/2021 | 494.28% | HC Wainwright & Co. | $175 → $185 | Maintains | Buy |
| 11/18/2020 | 253.36% | Canaccord Genuity | $108 → $110 | Maintains | Buy |
| 09/02/2020 | 163.41% | Jefferies | → $82 | Initiates Coverage On | → Buy |
| 08/17/2020 | 205.17% | BMO Capital | $104 → $95 | Maintains | Outperform |
| 08/17/2020 | 462.16% | HC Wainwright & Co. | $200 → $175 | Maintains | Buy |
| 07/21/2020 | 285.48% | Canaccord Genuity | $71 → $120 | Maintains | Buy |
| 07/20/2020 | 542.47% | HC Wainwright & Co. | $120 → $200 | Maintains | Buy |
| 07/13/2020 | 102.38% | B of A Securities | $53 → $63 | Reiterates | → Buy |
| 07/08/2020 | 285.48% | HC Wainwright & Co. | $95 → $120 | Reiterates | → Buy |
| 06/04/2020 | 224.45% | Guggenheim | → $101 | Initiates Coverage On | → Buy |
| 04/01/2020 | 44.56% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 02/26/2020 | 205.17% | HC Wainwright & Co. | $30 → $95 | Reiterates | → Buy |
| 02/21/2020 | 118.44% | Canaccord Genuity | $27 → $68 | Maintains | Buy |
| 02/14/2020 | 381.85% | SunTrust Robinson Humphrey | $24 → $150 | Maintains | Buy |
| 01/08/2020 | -3.63% | HC Wainwright & Co. | $25 → $30 | Maintains | Buy |
| 11/12/2019 | -22.9% | SunTrust Robinson Humphrey | → $24 | Initiates Coverage On | → Buy |
| 05/03/2018 | -19.69% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/02/2018 | -51.81% | Barclays | → $15 | Initiates Coverage On | → Overweight |
| 04/02/2018 | -42.18% | UBS | → $18 | Initiates Coverage On | → Buy |
| 04/02/2018 | -26.12% | BMO Capital | → $23 | Initiates Coverage On | → Outperform |
| 04/02/2018 | -32.54% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 01/26/2023 | -16.48% | 高盛 | $16 → $26 | 维护 | 中性 |
| 01/03/2023 | 134.5% | HC Wainwright公司 | $85 → $73 | 维护 | 买 |
| 12/01/2022 | -48.6% | 高盛 | → $16 | 升级 | 卖出→中性 |
| 11/16/2022 | -42.18% | 瑞穗 | $19 → $18 | 维护 | 买 |
| 11/11/2022 | -19.69% | 古根海姆 | $28 → $25 | 维护 | 买 |
| 11/11/2022 | 144.14% | 卡纳科特·格纳奇 | $75 → $76 | 维护 | 买 |
| 11/11/2022 | -42.18% | 瑞穗 | $19 → $18 | 维护 | 买 |
| 08/24/2022 | 173.05% | HC Wainwright公司 | $110 → $85 | 维护 | 买 |
| 07/07/2022 | -38.97% | 瑞穗 | → $19 | 开始承保 | →购买 |
| 05/23/2022 | 253.36% | HC Wainwright公司 | $134 → $110 | 维护 | 买 |
| 04/14/2022 | 330.45% | HC Wainwright公司 | $130 → $134 | 维护 | 买 |
| 03/14/2022 | 317.6% | HC Wainwright公司 | $140 → $130 | 维护 | 买 |
| 02/16/2022 | -19.69% | 瑞银集团 | $88 → $25 | 维护 | 买 |
| 11/15/2021 | -22.9% | 高盛 | $55 → $24 | 评级下调 | Buy→Sell |
| 06/28/2021 | 349.73% | HC Wainwright公司 | $176 → $140 | 维护 | 买 |
| 06/23/2021 | 301.54% | Truist证券 | $128 → $125 | 维护 | 买 |
| 06/01/2021 | 465.37% | HC Wainwright公司 | $170 → $176 | 维护 | 买 |
| 05/11/2021 | 446.1% | HC Wainwright公司 | $175 → $170 | 维护 | 买 |
| 04/09/2021 | 140.93% | 贝伦伯格 | → $75 | 开始承保 | →购买 |
| 04/01/2021 | 205.17% | 卡纳科特·格纳奇 | $110 → $95 | 维护 | 买 |
| 04/01/2021 | 307.97% | Truist证券 | $150 → $127 | 维护 | 买 |
| 04/01/2021 | 462.16% | HC Wainwright公司 | $185 → $175 | 维护 | 买 |
| 02/01/2021 | 218.02% | 瑞银集团 | → $99 | 开始承保 | →购买 |
| 01/06/2021 | 494.28% | HC Wainwright公司 | $175 → $185 | 维护 | 买 |
| 11/18/2020 | 253.36% | 卡纳科特·格纳奇 | $108 → $110 | 维护 | 买 |
| 09/02/2020 | 163.41% | 杰富瑞 | → $82 | 开始承保 | →购买 |
| 08/17/2020 | 205.17% | 蒙特利尔银行资本 | $104 → $95 | 维护 | 跑赢大盘 |
| 08/17/2020 | 462.16% | HC Wainwright公司 | $200 → $175 | 维护 | 买 |
| 07/21/2020 | 285.48% | 卡纳科特·格纳奇 | $71 → $120 | 维护 | 买 |
| 07/20/2020 | 542.47% | HC Wainwright公司 | $120 → $200 | 维护 | 买 |
| 07/13/2020 | 102.38% | B of A证券 | $53 → $63 | 重申 | →购买 |
| 07/08/2020 | 285.48% | HC Wainwright公司 | $95 → $120 | 重申 | →购买 |
| 06/04/2020 | 224.45% | 古根海姆 | → $101 | 开始承保 | →购买 |
| 04/01/2020 | 44.56% | B of A证券 | → $45 | 开始承保 | →购买 |
| 02/26/2020 | 205.17% | HC Wainwright公司 | $30 → $95 | 重申 | →购买 |
| 02/21/2020 | 118.44% | 卡纳科特·格纳奇 | $27 → $68 | 维护 | 买 |
| 02/14/2020 | 381.85% | SunTrust Robinson Humphrey | $24 → $150 | 维护 | 买 |
| 01/08/2020 | -3.63% | HC Wainwright公司 | $25 → $30 | 维护 | 买 |
| 11/12/2019 | -22.9% | SunTrust Robinson Humphrey | → $24 | 开始承保 | →购买 |
| 05/03/2018 | -19.69% | HC Wainwright公司 | → $25 | 开始承保 | →购买 |
| 04/02/2018 | -51.81% | 巴克莱 | → $15 | 开始承保 | →超重 |
| 04/02/2018 | -42.18% | 瑞银集团 | → $18 | 开始承保 | →购买 |
| 04/02/2018 | -26.12% | 蒙特利尔银行资本 | → $23 | 开始承保 | →跑赢大盘 |
| 04/02/2018 | -32.54% | 卡纳科特·格纳奇 | → $21 | 开始承保 | →购买 |
What is the target price for BioXcel Therapeutics (BTAI)?
BioXcel治疗公司(BTAI)的目标价格是多少？
The latest price target for BioXcel Therapeutics (NASDAQ: BTAI) was reported by Goldman Sachs on January 26, 2023. The analyst firm set a price target for $26.00 expecting BTAI to fall to within 12 months (a possible -16.48% downside). 13 analyst firms have reported ratings in the last year.
高盛于2023年1月26日报道了BioXcel治疗公司(纳斯达克：BTAI)的最新目标价。这家分析公司将目标价定为26.00美元，预计BTAI将在12个月内降至(可能下跌16.48%)。过去一年，有13家分析公司公布了评级。
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
BioXcel治疗公司(BTAI)的最新分析师评级是什么？
The latest analyst rating for BioXcel Therapeutics (NASDAQ: BTAI) was provided by Goldman Sachs, and BioXcel Therapeutics maintained their neutral rating.
高盛提供了对BioXcel治疗公司(纳斯达克代码：BTAI)的最新分析师评级，BioXcel治疗公司维持其中性评级。
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
BioXcel治疗公司(BTAI)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与BioXcel治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BioXcel治疗公司的上一次评级是在2023年1月26日提交的，所以你应该预计下一次评级将在2024年1月26日左右的某个时候提供。
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
分析师对BioXcel治疗公司(BTAI)的评级正确吗？
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a maintained with a price target of $16.00 to $26.00. The current price BioXcel Therapeutics (BTAI) is trading at is $31.13, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的BioXcel治疗公司(BTAI)评级保持不变，目标价在16.00美元至26.00美元之间。BioXcel治疗公司(BTAI)目前的交易价格为31.13美元，超出了分析师的预测范围。